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Beyond the individual health benefit of 
vaccinations, the population-related ef-
fectiveness of vaccinations is dependent 
on high vaccination coverage. This is the 
only way individuals who are too young 
or too ill for a vaccination can be effec-
tively protected against diseases through 
the protective effect of so-called herd im-
munity. The health benefit and economic 
benefit of vaccinations can only be maxi-
mised through high vaccination coverage. 
Once herd immunity is achieved vaccina-
tion will more than proportionately re-
duce the morbidity rate and increase the 
average length of outbreak-free intervals 
[1]. Individual vaccination decisions are 
dependent on the subjective benefit–risk 
assessment of each individual [2, 3]. In 
times of decreasing or low incidence the 
risk of contracting diseases decreases, but 
actual or feared vaccination risks are in-
creasingly perceived. Therefore achieving 
and maintaining high vaccination cover-
age represents an ongoing challenge.
Current data on incidence and vacci-
nation coverage provide the basis for ev-
idence-based health policy decisions in 
the field of vaccination. Vaccination cov-
erage is defined as the number of individ-
uals in a population who have received a 
vaccination or series of vaccinations in re-
lation to the total number of individuals 
in the population. As vaccination cover-
age in Germany is not recorded in an im-
munisation register, monitoring vaccina-
tion coverage comprises data from differ-
ent sources. While for children the school 
entry examinations provide data on vac-
cination status for at least one age group, 
information regarding adults in Germa-
ny was, until recently, only available from 
small, sporadic surveys [4, 5, 6] and eval-
uations of statutory health insurance data 
[7] and were mainly focussed on influenza 
vaccinations. Much time has passed since 
representative population surveys on vac-
cination coverage such as the microcensus 
by the Federal Statistics Office [8] or the 
German National Health Interview and 
Examination Survey 1998 (GNHIES98) 
have been carried out. The aim of this 
paper is to present an overview of vacci-
nation coverage for standard and select-
ed indication vaccinations recommend-
ed by the Standing Committee on Vacci-
nation Recommendations at the Robert 
Koch Institute (STIKO). Differences in 
vaccination coverage by age, sex and so-
cial status will be analysed and the multi-
mode method will be considered. For tet-
anus and diphtheria, the current vaccina-
tion coverage data will be compared with 
the data from 10 years ago.
Methods
The German Health Interview and Ex-
amination Survey for Adults (“Studie zur 
Gesundheit Erwachsener in Deutsch-
land”, DEGS) is part of the health moni-
toring system at the Robert Koch Institute 
(RKI). The concept and design of DEGS 
are described in detail elsewhere [9, 10, 11, 
12, 13]. The first wave (DEGS1) was con-
ducted from 2008–2011 and comprised in-
terviews, examinations and tests [14, 15]. 
The target population comprises the res-
idents of Germany aged 18–79 years. The 
study design of DEGS1 is mixed permit-
ting cross-sectional and longitudinal anal-
yses. For this purpose, a random sam-
ple from local population registries was 
drawn to complete the participants from 
German National Health Interview and 
Examination Survey 1998 (GNHIES98). A 
total of 8,152 persons participated, includ-
ing 4,193 first-time participants (response 
rate 42%) and 3,959 revisiting participants 
of GNHIES98 (response rate 62%). There 
were 7,238 persons who attended one of 
180 examination centres, and 914 were in-
terviewed only. The net sample (n=7,988) 
permits representative cross-sectional and 
trend analyses for the age range of 18–
79 years in comparison with GNHIES98 
(n=7,988, including 7,116 in study cen-
tres) [10]. The data of the revisiting partic-
ipants can be used for longitudinal analy-
ses. The cross-sectional and trend analy-
ses are carried out with a weighting fac-
tor which corrects deviations in the sam-
ple from the population structure (as of 
31 Dec 2010) with respect to age, sex, re-
gion and nationality as well as communi-
ty type and education [10].
A separate weighting factor was gener-
ated for the examination part of the study. 
Calculation of the weighting factor also 
considered re-participation probability of 
former GNHIES98 participants, based on 
a logistic regression model. For the pur-
pose of conducting trend analyses, the da-
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ta from the GNHIES98 were age-adjusted 
to the population level as of 31 Dec 2010. A 
non-responder analysis and a comparison 
of selected indicators with data from cen-
sus statistics indicate a high level of rep-
resentativity of the net sample for the res-
idential population aged 18–79 years of 
Germany [10].
To take into account both the weight-
ing as well as the correlation of partici-
pants within a community, the confi-
dence intervals were determined with 
the SPSS 20 procedures complex sam-
ples. Differences are considered statisti-
cally significant if the 95% confidence in-
tervals do not overlap. The vaccination 
coverage was stratified by sex, age, socio-
economic status (SES) and place of resi-
dence in eastern or western Germany. So-
cioeconomic status was determined using 
an index which includes information on 
school education and vocational training, 
professional status and net household in-
come (weighted by household needs), 
permitting classification into low, mid-
dle and high status groups [16]. The par-
ticipants were asked to bring their vac-
cination documents (vaccination card 
and vaccination certificates) to the medi-
cal examination. In the examination cen-
tre, completeness of the submitted vacci-
nation documents were checked by the 
study physician—taking into account the 
details provided by participants—and 
then copied. If the documents were com-
plete, the data for medically documented 
vaccinations were entered at the Robert 
Koch Institute by specially trained, med-
ically experienced personnel; no com-
puter-assisted personal interview (CAPI) 
was carried out, however. In the absence 
of a vaccination card or if the submitted 
vaccination documents were incomplete, 
then the vaccination status was recorded 
(additionally) in CAPI. Subjects who had 
not submitted a vaccination card for the 
medical examination were asked to send 
it in at a later date. The basis of the vac-
cination coverage data presented here is 
therefore the vaccinations documented 
in the vaccination card, details provided 
by participants in the CAPI interview and 
information used from both sources. In 
the CAPI, data for lifetime prevalence for 
at least one dose of each vaccination was 
collected using the question “Have you 
ever been vaccinated against…?” For tet-
anus, diphtheria and pertussis (whooping 
cough) participants were asked if the vac-
cination took place within the last 10 years 
in order to determine the 10-year preva-
lence. The vaccination data documented 
in the vaccination card was processed ac-
cording to these questions. Furthermore, 
notes on vaccinations submitted togeth-
er with the vaccination card that did not 
correspond to a medically documented 
vaccination were collected and taken in-
to account on equal terms with the self-
reported data in the CAPI.
Results
Data regarding vaccination status were 
obtained for 99.0% of participants 
(. Tab. 1). For two thirds of adults, the 
vaccination status is based complete-
ly (40.8%) or partially (26.8%) on infor-
mation from vaccination cards. Women 
submitted a vaccination card significant-
ly more often than men. The proportion 
of complete vaccination cards was high-
est in women aged 18–29 years, the pro-
portion was lowest in 60- to 69-year-old 
men. In general it was observed that vac-
cination information could be based less 
and less on vaccination cards alone as the 
age of participants increased. In older age 
groups vaccination status was more often 
based on the combination of data from the 
vaccination card and the CAPI.
The proportion of participants for 
whom no information for the respec-
Tab. 1 DEGS1: Source of information for vaccination status in study participants by sex and age group in percent with 95% confidence intervals. 
nunweighted=7988
  Age group
Data source 18–29 30–39 40–49 50–59 60–69  70–79 Total
Women
Vaccination card 65.7 (60.9–70.3) 43.6 (38.5–48.8) 47.0 (42.1–51.8) 39.4 (34.7–44.2) 35.0 (29.8–40.6) 30.2 (24.8–36.2) 44.4 (41.7–47.2)
CAPI 21.7 (17.4–26.8) 38.3 (33.0–43.9) 30.3 (26.4–34.5) 27.4 (24.1–30.9) 24.9 (21.3–28.9) 27.6 (23.5–32.1) 28.2 (26.3–30.3)
Card and CAPI 12.1 (9.2–15.7) 17.2 (13.4–21.8) 22.1 (18.4–26.3) 31.9 (27.7–36.6) 39.0 (33.8–44.5) 41.2 (35.3–47.3) 26.5 (23.9–29.2)
No vaccination 
data
0.4 (0.1–1.4) 0.9 (0.2–3.5) 0.7 (0.3–1.5) 1.3 (0.6–2.7) 1.1 (0.3–4.0) 1.0 (0.4–2.4) 0.9 (0.5–1.5)
Men
Vaccination card 56.3 (50.7–61.7) 39.3 (33.7–45.1) 32.1 (27.5–37.2) 32.2 (27.2–37.6) 29.0 (24.6–33.9) 30.0 (24.6–36.0) 37.2 (34.3–40.2)
CAPI 31.7 (26.8–37.1) 39.2 (34.3–44.3) 36.6 (31.6–41.9) 32.9 (28.9–37.1) 32.9 (28.8–37.3) 34.7 (29.8–39.9) 34.6 (32.1–37.2)
Card and CAPI 10.5 (7.7–14.0) 20.5 (16.0–25.9) 30.1 (25.4–35.2) 33.7 (28.8–38.9) 37.5 (32.5–42.7) 34.9 (29.5–40.8 27.1 (24.5–29.8)
No vaccination 
data
1.5 (0.5–4.2) 1.1 (0.4–3.2) 1.2 (0.5–3.1) 1.2 (0.5–2.8) 0.6 (0.2–1.3) 0.4 (0.1–1.3) 1.1 (0.7–1.7)
Total
Vaccination card 60.9 (57.1–64.5) 41.4 (37.6–45.3) 39.4 (35.6–43.3) 35.8 (32.0–39.8) 32.1 (28.0–36.5) 30.1 (25.3–35.3) 40.8 (38.3–43.4)
CAPI 26.9 (23.4–30.6) 38.7 (35.2–42.3) 33.5 (30.2–37.0) 30.1 (27.6–32.8) 28.8 (26.1–31.7) 30.8 (27.5–34.3) 31.4 (29.7–33.2)
Card and CAPI 11.3 (9.3–13.6) 18.9 (15.7–22.4) 26.2 (22.8–29.8) 32.8 (29.0–36.8) 38.2 (34.3–42.4) 38.4 (33.7–43.2) 26.8 (24.5–29.1)
No vaccination 
data
1.0 (0.4–2.5) 1.0 (0.4–2.4) 0.9 (0.4–2.0) 1.3 (0.7–2.2) 0.9 (0.3–2.1) 0.7 (0.4–1.6) 1.0 (0.7–1.4)




tive vaccination status could be obtained 
varied widely depending on the vaccina-
tion in question. While no information 
regarding influenza status could be ob-
tained for only 2.9% of adults, the figure 
for pertussis was 11.1% (data not shown). 
Information regarding the number of 
missing values can be drawn from the 
data for unweighted case numbers in 
. Tab. 2.
Lifetime prevalence
Vaccination prevalences by sex and age 
group are shown in . Tab. 2. Vaccina-
tion coverage is highest for active im-
munisation against tetanus (96.0%). Vac-
cination coverage is statistically signifi-
cantly higher in men (97.0%; 95% con-
fidence interval (CI) 96.2–97.7) than in 
women (95.0%; 95% CI 94.0–95.9). 81.5% 
of adults are vaccinated against diphthe-
ria with at least one vaccine dose. In con-
trast to tetanus vaccination coverage 
women are more likely to be vaccinated 
than men. The study showed that 85.6% 
of adults are vaccinated against poliomy-
elitis; the higher vaccination coverage in 
women in comparison to men is particu-
larly evident in 50–59 year olds. 34.5% of 
adults have received at least one vaccine 
dose against pertussis; while there is no 
difference by sex in the 18–29 age groups, 
30- to 59-year-old women are slight-
ly more often vaccinated against pertus-
sis than men in this age group. 32.9% of 
adults have received at least one vaccine 
dose against hepatitis B; as with pertus-
sis, women are more likely to be vacci-
nated than men, with the largest differ-
ence being observed in 40–59 year olds. 
Overall lifetime prevalence of influen-
za vaccination is 44.7%; there is no dif-
ference between women and men. 27.4% 
of adults have received at least one vacci-
nation against hepatitis A. The vaccina-
tion coverage for tick-borne encephalitis 
(TBE) is 29.4%.
While vaccination coverage against tet-
anus is only lower in 70–79 year olds in 
comparison to the other age groups, there 
is a clear decrease in prevalence for vacci-
nations against diphtheria and poliomy-
elitis as the age increases; this decrease 
can be seen even more clearly for vacci-
nations against pertussis and hepatitis A 
and B. In contrast, lifetime prevalence of 
influenza vaccination increases signifi-
cantly with age. The highest vaccination 
coverage is observed in 70- to 79-year-
old adults (68.3%), whereas 30.8% of peo-
ple in the 18–29 age group are vaccinated 
against influenza (including influenza A 
(H1N1) virus).
Vaccination during the last 10 years
A total of 71.4% of adults have been vacci-
nated against tetanus within the preceding 
10 years and can be classified as current-
ly vaccinated against tetanus. The vacci-
nation coverage is highest in young adults 
aged 18–29 and is lowest in 30–39 year 
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Abstract
In the absence of an immunisation register, 
vaccination coverage in Germany must be es-
timated. Ten years after the German Nation-
al Health Interview and Examination Sur-
vey 1998 (GNHIES98), the population sur-
vey DEGS1 is one of the data sources that 
can be used for monitoring vaccination cov-
erage. In the survey, data on vaccination his-
tory were obtained from vaccination cards 
and self-reports. The prevalence of immuni-
sation for tetanus and diphtheria was high-
er compared to the prevalence estimated 
10 years previously in GNHIES98. Nonethe-
less, 28.6% of adults have not been vaccinat-
ed against tetanus and 42.9% have not been 
vaccinated against diphtheria within the last 
10 years. Vaccination is especially low among 
the elderly, among adults with low socioeco-
nomic status and in western Germany. Dur-
ing the last 10 years, only 11.8% of wom-
en and 9.4% of men were vaccinated against 
pertussis in western Germany; vaccination 
coverage was twice as high in eastern Ger-
many. In 2009, recommendations were pub-
lished to combine the next tetanus immuni-
sation with a pertussis immunisation; there-
fore pertussis vaccination coverage might im-
prove in the coming years. The lifetime prev-
alence of influenza vaccination obtained in 
DEGS1 is higher than the annual vaccination 
rate for influenza. However, the lifetime prev-
alence among adults aged 60 years or old-
er is still below the annual rate of 75% recom-
mended by the WHO.
Keywords
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Impfstatus von Erwachsenen in Deutschland. Ergebnisse der 
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Zusammenfassung
In Deutschland werden Impfquoten nicht 
über ein Impfregister erfasst. Die bevölke-
rungsrepräsentative Studie zur Gesundheit 
Erwachsener in Deutschland (DEGS1) ist ein 
Baustein für das Monitoring der Durchimp-
fung. Zur Erhebung der Impfdaten wurden 
Impfpässe und Befragungsdaten genutzt. Der 
Tetanus- und Diphtherie-Impfstatus Erwach-
sener ist besser als vor 10 Jahren im „Bundes-
Gesundheitssurvey 1998“, dennoch haben 
immer noch 28,6% der Bevölkerung in den 
letzten 10 Jahren keine Tetanusimpfung und 
42,9% keine Diphtherieimpfung erhalten. 
Insbesondere bei Älteren, bei Erwachsenen 
mit niedrigem sozioökonomischem Status 
und in Westdeutschland bestehen Impf-
lücken. Nur 11,8% der Frauen und 9,4% der 
Männer in Westdeutschland haben innerhalb 
der letzten 10 Jahre eine Impfung gegen Per-
tussis erhalten; die Durchimpfung ist in Ost-
deutschland doppelt so hoch. Die seit 2009 
bestehende Empfehlung, mit der nächst-
anstehenden Tetanusimpfung gleichzeitig 
gegen Pertussis zu impfen, lässt jedoch einen 
Anstieg der Durchimpfung erwarten. Im Ver-
gleich zu den jährlichen Impfraten gegen In-
fluenza ist der Anteil jemals gegen Influen-
za geimpfter Erwachsener höher. Allerdings 
liegt bei Frauen und Männern im Alter über 
60 Jahren selbst die Lebenszeitprävalenz 
deutlich unter der von der Weltgesundheits-
organisation (WHO) empfohlenen jährlichen 
Impfrate von 75%.
Schlüsselwörter
Gesundheitssurvey · Impfquoten · 
Allgemeinbevölkerung · Erwachsene · 
Deutschland
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Tab. 2 Vaccination coverage of at least one vaccination dose by sex and age group in percent with 95% confidence intervals. 




18–29  30–39  40–49  50–59  60–69  70–79  Total
Tetanus
Women 4092 95.5 (92.2–97.4) 96.2 (93.2–97.9) 96.2 (94.2–97.6) 95.4 (93.5–96.8) 94.4 (91.5–96.4) 91.4 (87.8–94.0) 95.0 (94.0–95.9)
Men 3701 98.0 (95.7–99.1) 98.0 (95.1–99.2) 97.6 (95.6–98.7) 97.4 (95.3–98.6) 95.1 (92.2–96.9) 94.9 (92.3–96.7) 97.0 (96.2–97.7)
Total 7793 96.8 (95.0–97.9) 97.1 (95.0–98.3) 96.9 (95.6–97.9) 96.4 (95.1–97.4) 94.7 (92.5–96.3) 93.0 (90.7–94.7) 96.0 (95.3–96.6)
Tetanus in the last 10 years
Women 4032 73.7 (68.8–78.0) 66.6 (61.1–71.6) 70.9 (66.7–74.8) 69.4 (65.4–73.1) 71.5 (67.1–75.6) 71.8 (67.1–76.1) 70.7 (68.8–72.6)
Men 3649 77.4 (72.2–81.8) 70.6 (64.8–75.7) 71.2 (66.6–75.4) 71.7 (67.6–75.4) 72.1 (67.7–76.1) 67.4 (61.8–72.5) 72.0 (70.0–74.0)
Total 7681 75.6 (71.8–78.9) 68.6 (64.4–72.4) 71.1 (67.9–74.0) 70.5 (67.6–73.3) 71.8 (68.4–75.0) 69.8 (66.2–73.2) 71.4 (69.8–72.9)
Diphtheria
Women 3881 91.1 (87.0–94.0) 86.0 (80.8–90.0) 87.6 (84.1–90.3) 85.3 (82.2–87.9) 78.8 (75.0–82.2) 71.9 (66.7–76.5) 84.1 (82.5–85.5)
Men 3393 90.6 (86.2–93.7) 84.8 (79.0–89.3) 78.5 (73.7–82.7) 72.8 (68.6–76.7) 73.4 (68.9–77.5) 69.3 (64.1–73.9) 78.7 (76.8–80.5)
Total 7274 90.9 (88.0–93.1) 85.5 (81.7–88.5) 83.1 (80.1–85.7) 79.1 (76.4–81.5) 76.2 (73.1–79.1) 70.7 (67.1–74.0) 81.5 (80.1–82.7)
Diphtheria in the last 10 years
Women 3792 67.6 (62.6–72.3) 55.4 (49.9–60.8) 61.0 (56.0–65.8) 57.1 (52.7–61.4) 59.1 (54.6–63.5) 55.7 (50.1–61.2) 59.6 (57.3–62.0)
Men 3308 69.6 (63.9–74.8) 54.3 (48.4–60.0) 52.5 (46.9–58.1) 48.4 (44.1–52.7) 50.5 (45.6–55.4) 49.8 (44.4–55.2) 54.5 (52.1–56.8)
Total 7100 68.6 (64.9–72.1) 54.9 (50.9–58.8) 56.8 (52.8–60.7) 52.8 (49.8–55.8) 55.0 (51.5–58.4) 53.0 (49.2–56.9) 57.1 (55.3–58.9)
Pertussis (whooping cough)
Women 3841 57.9 (52.4–63.3) 52.7 (46.8–58.5) 42.4 (37.8–47.2) 27.0 (23.1–31.2) 19.9 (16.4–24.0) 14.7 (11.4–18.6) 36.6 (34.2–39.0)
Men 3374 56.5 (50.5–62.2) 46.1 (39.9–52.4) 35.5 (30.5–40.7) 19.5 (16.3–23.3) 16.4 (13.1–20.4) 13.3 (10.3–17.1) 32.3 (29.7–35.0)
Total 7215 57.2 (53.2–61.1) 49.4 (44.8–54.1) 38.9 (35.1–42.8) 23.3 (20.5–26.4) 18.2 (15.6–21.2) 14.1 (11.6–17.0) 34.5 (32.3–36.7)
Pertussis in the last 10 years
Women 3766 30.6 (25.9–35.7) 12.1 (9.2–15.7) 12.2 (9.5–15.6) 10.6 (8.2–13.5) 7.1 (5.2–9.7) 6.9 (4.6–10.2) 13.7 (12.1–15.4)
Men 3317 26.2 (21.5–31.4) 8.9 (6.2–12.5) 10.8 (8.1–14.3) 4.8 (3.4–6.8) 7.8 (5.2–11.5) 7.8 (5.4–11.2) 11.4 (9.9–13.0)
Total 7083 28.4 (24.8–32.4) 10.5 (8.3–13.2) 11.5 (9.4–13.9) 7.7 (6.2–9.6) 7.5 (5.6–9.9) 7.3 (5.4–9.8) 12.5 (11.3–14.0)
Poliomyelitis
Women 4021 94.3 (90.8–96.5) 89.1 (84.7–92.4) 89.7 (86.0–92.5) 91.7 (88.9–93.9) 82.8 (78.5–86.5) 70.2 (64.9–75.0) 87.1 (85.3–88.7)
Men 3594 91.0 (86.8–93.9) 89.6 (84.6–93.0) 89.4 (85.5–92.3) 83.6 (79.5–86.9) 78.3 (73.8–82.2) 65.3 (59.3–70.8) 84.2 (82.2–86.0)
Total 7615 92.6 (90.1–94.6) 89.3 (86.2–91.8) 89.5 (86.9–91.7) 87.6 (85.2–89.7) 80.6 (77.4–83.5) 68.0 (63.8–71.9) 85.6 (84.2–87.0)
Influenza (flu)
Women 4124 26.9 (22.8–31.5) 28.3 (23.5–33.6) 37.2 (32.8–41.9) 42.9 (38.5–47.5) 65.0 (60.4–69.4) 67.6 (62.7–72.2) 43.4 (41.0–45.8)
Men 3697 34.6 (29.4–40.2) 36.2 (30.1–42.7) 40.2 (35.5–45.1) 45.0 (40.3–49.8) 62.6 (57.7–67.2) 69.2 (63.3–74.5) 46.1 (43.5–48.6)
Total 7821 30.8 (27.2–34.7) 32.2 (28.1–36.6) 38.7 (35.2–42.3) 44.0 (40.4–47.6) 63.8 (60.2–67.3) 68.3 (64.4–72.0) 44.7 (42.6–46.8)
Hepatitis A
Women 3909 40.0 (35.6–44.5) 34.8 (30.1–39.8) 29.5 (25.4–34.0) 24.5 (21.2–28.3) 20.6 (16.6–25.4) 12.3 (9.6–15.7) 27.4 (25.4–29.5)
Men 3480 41.3 (36.2–46.6) 37.1 (31.4–43.2) 27.4 (23.4–31.8) 22.1 (18.6–26.1) 20.5 (16.6–24.9) 11.3 (8.7–14.6) 27.3 (25.2–29.5)
Total 7389 40.6 (37.1–44.3) 35.9 (32.1–39.9) 28.4 (25.5–31.6) 23.3 (20.6–26.2) 20.6 (17.6–23.8) 11.9 (9.9–14.1) 27.4 (25.7–29.1)
Hepatitis B
Women 3912 76.3 (71.8–80.3) 37.7 (32.4–43.3) 33.5 (29.6–37.5) 25.3 (21.6–29.5) 17.3 (13.7–21.7) 9.7 (7.1–13.1) 34.4 (32.4–36.5)
Men 3464 73.3 (68.2–77.9) 35.7 (30.2–41.7) 25.6 (21.5–30.1) 20.0 (16.6–23.9) 15.5 (12.1–19.6) 9.4 (7.0–12.5) 31.3 (29.1–33.6)
Total 7376 74.8 (71.3–78.1) 36.8 (32.7–41.0) 29.5 (26.5–32.6) 22.7 (19.8–25.8) 16.4 (14.0–19.2) 9.5 (7.6–11.9) 32.9 (31.3–34.5)
Tick-borne encephalitis
Women 4036 38.8 (33.7–44.1) 27.0 (22.0–32.5) 29.1 (24.4–34.2) 25.2 (21.2–29.7) 28.3 (23.5–33.7) 25.0 (19.5–31.3) 29.1 (25.9–32.5)
Men 3636 44.5 (38.6–50.6) 28.0 (23.2–33.3) 25.4 (21.1–30.4) 25.1 (20.7–30.0) 28.1 (23.2–33.6) 25.6 (21.1–30.7) 29.7 (26.6–33.0)
Total 7672 41.7 (37.2–46.2) 27.5 (23.6–31.7) 27.2 (23.4–31.4) 25.2 (21.6–29.1) 28.2 (24.4–32.4) 25.3 (21.1–29.9) 29.4 (26.5–32.4)
Meningococci
Women 3953 8.3 (5.8–11.7) 3.3 (1.8–6.1) 1.9 (1.2–3.3) 1.7 (0.8–3.9) 1.4 (0.6–3.2) 0.8 (0.4–1.9) 3.0 (2.4–3.7)
Men 3493 9.0 (6.5–12.4) 2.3 (1.0–5.4) 1.9 (1.0–3.5) 1.9 (0.9–4.1) 2.7 (1.2–6.0) 0.8 (0.2–3.0) 3.2 (2.5–4.1)




olds and 70–79 year olds. The proportion 
of adults who have been vaccinated against 
diphtheria within the last 10 years is 57.1% 
and is significantly higher in women as 
compared to men. The relative difference 
between lifetime prevalence of a vaccina-
tion and the prevalence of a vaccination 
within the last 10 years is highest between 
pertussis vaccinations (34.5%; 32.3–36.7 
versus 12.5%; 11.3–14.0); this discrepancy 
is smallest for 18–29 year olds and largest 
for 30–39 year olds. There are no signifi-
cant differences by sex (. Tab. 2).
Vaccination coverage (lifetime prev-
alence for at least one vaccine dose) for 
measles, mumps, rubella and pneumo-
cocci are shown in . Tab. 3. In total, 
38.1% of 18–64 year olds have been vacci-
nated against measles, with 30.1% vacci-
nated against mumps. Vaccination cover-
age for measles is highest in the 18–29 age 
group (79.8%) and decreases with age 
to 3.8% among 60–64 year olds. Rubel-
la vaccinations were recorded in 34.6% 
of 18–64 year olds. As with measles and 
mumps, the prevalence decreases with 
age. In the 18–49 age groups, women are 
statistically significantly more likely to be 
vaccinated against rubella than men. In 
all 31.4% of adults aged between 65 and 
79 have been vaccinated against pneu-




Vaccination coverage for women and 
men stratified by SES is shown in 
. Tab. 4. Vaccination coverage against 
tetanus, diphtheria, poliomyelitis, per-
tussis, hepatitis A and hepatitis B de-
creases as SES decreases. Differences 
between high and middle and between 
middle and low SES are statistically sig-
nificant for most vaccinations. Differ-
ent association between SES and vacci-
nation coverage is found for measles and 
mumps (data for mumps not shown), for 
vaccinations against influenza in wom-
en and for vaccinations against rubel-
la in men. For these vaccinations there 
is slightly higher coverage in adults with 
low SES compared to adults with high 
SES; however, vaccination coverage does 
not differ (except for the differences for 
rubella vaccinations in men) significant-
ly by SES. SES is not associated with cov-
erage of vaccination against pneumococ-
ci and against influenza in men.
Vaccination in eastern and 
western Germany
Vaccination coverage stratified by resi-
dency in eastern and western Germany is 
shown in . Tab. 5. Vaccination coverage 
is higher in eastern Germany for tetanus, 
diphtheria and pertussis. While the as-
sociation between vaccination coverage 
and SES was obvious for lifetime preva-
lences, differences between east and west 
are more pronounced for vaccination 
coverage within the last 10 years. The 
east–west difference is particularly evi-
dent with vaccination coverage for per-
tussis (women: 22.9% versus 11.8%; men: 
20.3% versus 9.4%). Considerable differ-
ences can also be observed in vaccination 
coverage for measles and influenza; cov-
erage is statistically significantly higher 
in eastern Germany than in western Ger-
many. In contrast, for hepatitis A, hepa-
titis  B and TBE (TBE data not shown), 
vaccination coverage is slightly higher in 
western Germany than in eastern Ger-
many; however, the differences are not 
statistically significant.
Tab. 3 Vaccination coverage of at least one vaccination dose for measles, mumps, rubella and pneumococci by sex and age group in percent 




18–29  30–39  40–49  50–59  60–64  65–79  Total
Measles
Women 2791 82.2 (77.7–86.0) 47.2 (41.3–53.1) 27.3 (23.3–31.8) 16.6 (13.6–20.0) 4.1 (2.0–8.1) n.r. 39.5 (37.0–42.1)
Men 2322 77.2 (71.6–81.9) 46.2 (40.1–52.4) 22.8 (18.6–27.6) 16.1 (12.9–19.9) 3.4 (1.7–6.4) n.r. 36.7 (33.9–39.5)
Total 5113 79.8 (76.3–82.9) 46.7 (42.2–51.2) 25.1 (21.8–28.7) 16.3 (14.0–19.0) 3.8 (2.3–6.0) n.r. 38.1 (36.0–40.3)
Mumps
Women 2770 77.8 (73.0–81.9) 31.2 (25.9–37.1) 14.3 (11.4–17.7) 11.0 (8.8–13.6) 3.3 (1.5–7.3) n.r. 30.7 (28.4–33.1)
Men 2302 73.7 (68.2–78.5) 31.3 (26.2–37.0) 13.7 (10.8–17.3) 11.8 (9.1–15.3) 2.8 (1.4–5.3) n.r. 29.5 (27.2–31.9)
Total 5072 75.8 (72.2–79.1) 31.3 (27.4–35.4) 14.0 (11.7–16.7) 11.4 (9.5–13.6) 3.1 (1.8–5.3) n.r. 30.1 (28.4–31.9)
Rubella
Women 2819 80.4 (75.9–84.1) 54.5 (48.5–60.5) 38.1 (34.0–42.4) 17.0 (14.0–20.4) 4.7 (2.5–8.7) n.r. 43.6 (41.3–46.0)
Men 2298 65.2 (59.3–70.6) 18.9 (15.0–23.5) 12.2 (9.4–15.8) 12.1 (9.4–15.5) 3.1 (1.6–6.2) n.r. 24.9 (22.7–27.3)
Total 5117 73.1 (69.6–76.3) 37.5 (33.3–41.9) 25.5 (22.8–28.4) 14.6 (12.4–17.0) 3.9 (2.5–6.3) n.r. 34.6 (32.9–36.3)
Pneumococci
Women 1015 n.r. n.r. n.r. n.r. n.r. 33.2 (29.0–37.6) 33.2 (29.0–37.6)
Men 965 n.r. n.r. n.r. n.r. n.r. 29.3 (25.3–33.6) 29.3 (25.3–33.6)
Total 1980 n.r. n.r. n.r. n.r. n.r. 31.4 (28.1–34.9) 31.4 (28.1–34.9)
n.r. not recorded.
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Tab. 4 Vaccination coverage by sex, age group and socioeconomic status in percent with 95% confidence intervals. nunweighted=depends on 
vaccination, see table
  Age group
Sex/social status nunweighted 18–29 30–44 45–64 65–79 Total
Tetanus
Women 4041      
Low 644 90.2 (78.6–95.8) 86.8 (74.5–93.7) 92.4 (87.5–95.5) 86.7 (77.8–92.4) 89.2 (85.2–92.2)
Middle 2515 96.5 (92.7–98.4) 98.2 (96.7–99.0) 96.0 (94.2–97.3) 94.5 (91.7–96.4) 96.3 (95.3–97.2)
High 882 99.5 (96.3–99.9) 99.4 (95.9–99.9) 97.0 (93.7–98.6) 97.5 (91.3–99.3) 98.2 (96.7–99.0)
Men 3648      
Low 570 95.7 (86.5–98.7) 89.7 (79.5–95.2) 95.7 (89.9–98.2) 91.0 (82.6–95.5) 93.4 (90.3–95.6)
Middle 2069 98.5 (95.4–99.5) 98.4 (95.7–99.4) 97.2 (95.1–98.4) 95.3 (92.7–97.0) 97.4 (96.5–98.1)
High 1009 100.0 (100.0–100.0) 99.8 (98.5–100.0) 98.7 (96.8–99.5) 98.0 (95.5–99.1) 99.1 (98.4–99.5)
Diphtheria
Women 3831      
Low 587 84.7 (71.4–92.4) 67.8 (52.7–79.9) 79.8 (71.9–85.9) 65.3 (55.7–73.8) 74.1 (68.9–78.7)
Middle 2395 91.4 (86.4–94.7) 90.2 (86.3–93.1) 85.1 (82.2–87.7) 78.1 (73.8–81.9) 86.0 (84.3–87.6)
High 849 99.4 (96.1–99.9) 93.5 (88.4–96.4) 87.1 (82.3–90.8) 82.1 (70.9–89.6) 90.5 (87.9–92.5)
Men 3348      
Low 521 86.6 (74.4–93.5) 60.1 (46.9–71.9) 64.0 (55.8–71.5) 63.0 (52.1–72.7) 67.8 (62.3–72.8)
Middle 1886 91.1 (85.8–94.5) 84.5 (78.2–89.2) 73.3 (68.9–77.2) 69.7 (64.5–74.4) 78.7 (76.1–81.1)
High 941 95.4 (83.8–98.8) 93.0 (86.8–96.4) 85.0 (80.1–88.8) 79.8 (72.7–85.5) 88.1 (85.2–90.4)
Pertussis
Women 3791      
Low 596 58.4 (46.8–69.2) 26.8 (16.7–39.9) 24.1 (17.6–31.9) 10.7 (6.5–17.1) 27.4 (23.1–32.1)
Middle 2364 55.6 (48.5–62.6) 54.0 (48.6–59.2) 28.9 (25.0–33.1) 17.1 (13.7–21.2) 37.3 (34.4–40.2)
High 831 64.6 (51.9–75.6) 56.6 (49.1–63.8) 34.4 (28.6–40.8) 23.2 (16.2–32.1) 44.7 (40.4–49.1)
Men 3327      
Low 518 52.6 (40.8–64.2) 34.6 (24.6–46.2) 17.7 (12.3–24.8) 15.8 (8.9–26.4) 28.5 (23.8–33.7)
Middle 1888 58.1 (51.2–64.6) 42.7 (36.4–49.2) 21.8 (18.2–25.9) 13.8 (10.5–18.0) 32.2 (29.1–35.4)
High 921 55.8 (40.3–70.3) 50.9 (42.1–59.7) 26.0 (20.6–32.2) 19.9 (13.9–27.7) 36.7 (31.9–41.7)
Poliomyelitis
Women 3970      
Low 617 88.2 (76.0–94.6) 72.7 (57.7–83.9) 81.6 (73.2–87.9) 61.3 (52.5–69.4) 74.9 (69.9–79.3)
Middle 2471 95.1 (91.0–97.4) 91.5 (87.4–94.4) 90.8 (88.0–92.9) 79.2 (74.6–83.1) 89.3 (87.5–90.9)
High 882 100.0 (100.0–100.0) 95.1 (89.4–97.8) 94.2 (90.7–96.4) 87.3 (78.6–92.8) 94.6 (92.1–96.3)
Men 3544      
Low 545 92.3 (82.2–96.9) 64.8 (52.7–75.2) 77.9 (70.5–83.9) 54.3 (44.1–64.2) 73.1 (67.8–77.9)
Middle 2010 89.0 (82.9–93.1) 92.9 (88.2–95.8) 84.6 (80.9–87.8) 65.9 (60.2–71.2) 84.0 (81.6–86.2)
High 989 98.4 (94.1–99.6) 97.2 (93.7–98.8) 95.6 (92.8–97.3) 82.2 (75.5–87.3) 94.3 (92.4–95.7)
Influenza
Women 4070      
Low 651 27.5 (18.8–38.3) 34.5 (23.2–48.0) 48.1 (39.6–56.8) 67.9 (60.2–74.7) 47.9 (43.0–52.9)
Middle 2534 27.2 (22.0–33.1) 29.2 (25.0–33.8) 45.6 (41.2–50.1) 69.8 (64.9–74.3) 43.2 (40.5–46.0)
High 885 23.7 (14.7–35.8) 33.8 (27.2–41.1) 41.3 (34.8–48.1) 65.4 (54.3–75.1) 38.9 (34.7–43.2)
Men 3643      
Low 580 39.2 (27.8–52.0) 32.9 (23.1–44.5) 54.9 (45.8–63.7) 63.2 (51.8–73.3) 48.3 (43.3–53.4)
Middle 2059 35.1 (28.6–42.2) 34.5 (28.6–40.9) 46.4 (41.8–51.1) 67.6 (62.1–72.7) 45.2 (42.2–48.2)




Tab. 4 Vaccination coverage by sex, age group and socioeconomic status in percent with 95% confidence intervals. nunweighted=depends on 
vaccination, see table (Continued)
  Age group
Sex/social status nunweighted 18–29 30–44 45–64 65–79 Total
Hepatitis A
Women 3858      
Low 608 25.1 (17.0–35.5) 17.4 (8.5–32.4) 19.0 (13.4–26.3) 8.0 (3.7–16.3) 16.3 (12.9–20.4)
Middle 2400 43.9 (38.1–49.9) 33.5 (28.7–38.8) 23.0 (19.7–26.8) 16.2 (13.1–20.0) 27.9 (25.5–30.4)
High 850 45.7 (33.9–58.0) 47.2 (39.6–54.9) 32.5 (27.5–37.8) 26.0 (18.9–34.5) 38.3 (34.2–42.6)
Men 3433      
Low 546 27.0 (18.0–38.3) 12.9 (7.0–22.7) 9.6 (5.5–16.4) 3.3 (1.4–7.5) 12.6 (9.5–16.4)
Middle 1940 40.8 (34.1–47.9) 30.2 (24.3–36.8) 21.1 (17.8–25.0) 13.0 (10.1–16.6) 25.5 (22.8–28.4)
High 947 61.8 (48.1–73.8) 54.1 (45.8–62.3) 36.6 (31.4–42.2) 29.3 (21.8–38.2) 44.2 (39.7–48.9)
Hepatitis B
Women 3861      
Low 611 74.8 (62.8–83.9) 20.1 (10.3–35.5) 22.9 (16.4–31.0) 7.5 (4.2–13.2) 28.0 (23.9–32.6)
Middle 2408 77.8 (72.4–82.4) 36.5 (31.5–41.8) 26.6 (23.1–30.4) 11.2 (8.4–14.8) 35.0 (32.6–37.5)
High 842 71.1 (57.6–81.6) 46.0 (38.4–53.8) 29.9 (24.6–35.8) 22.2 (14.7–32.1) 40.2 (36.2–44.4)
Men 3416      
Low 541 55.6 (43.0–67.5) 11.7 (6.2–21.0) 7.5 (4.1–13.3) 4.2 (1.8–9.3) 17.8 (14.1–22.3)
Middle 1930 76.1 (70.0–81.3) 29.5 (24.1–35.5) 19.2 (15.8–23.3) 10.3 (7.7–13.7) 31.2 (28.3–34.1)
High 945 86.9 (76.4–93.1) 49.3 (40.6–58.1) 31.6 (26.2–37.5) 23.9 (17.2–32.2) 43.1 (38.9–47.5)
Measles
Women 2758     18–64
Low 376 82.1 (70.4–89.8) 36.7 (23.7–51.9) 23.6 (17.1–31.5) n.r. 45.5 (39.4–51.8)
Middle 1708 82.7 (76.7–87.5) 43.7 (38.3–49.2) 14.3 (11.8–17.3) n.r. 39.3 (36.3–42.3)
High 674 82.0 (69.3–90.2) 45.5 (37.7–53.5) 13.2 (9.1–18.8) n.r. 37.0 (32.2–42.2)
Men 2303      
Low 356 75.5 (63.4–84.6) 24.8 (16.5–35.3) 20.9 (14.5–29.2) n.r. 37.6 (31.6–44.0)
Middle 1309 77.3 (69.7–83.5) 37.9 (31.2–45.1) 15.1 (12.1–18.7) n.r. 37.4 (33.8–41.0)
High 638 78.6 (65.0–87.9) 42.5 (34.5–51.0) 12.7 (8.7–18.3) n.r. 34.4 (29.6–39.7)
Rubella
Women 2787      
Low 372 79.6 (68.4–87.5) 32.8 (20.7–47.8) 21.1 (14.3–30.0) n.r. 43.0 (37.1–49.2)
Middle 1733 80.1 (74.0–85.0) 55.9 (50.2–61.5) 18.5 (15.5–22.1) n.r. 44.4 (41.5–47.3)
High 682 84.5 (72.4–91.9) 56.9 (49.2–64.2) 15.9 (11.9–20.9) n.r. 43.3 (39.0–47.7)
Men 2282      
Low 356 66.4 (52.8–77.7) 12.0 (6.6–20.8) 17.1 (11.4–24.8) n.r. 29.4 (23.8–35.8)
Middle 1295 66.6 (58.9–73.6) 16.9 (12.7–22.1) 10.1 (7.7–13.1) n.r. 26.2 (23.4–29.3)
High 631 56.2 (41.7–69.7) 15.5 (10.3–22.6) 9.2 (6.2–13.6) n.r. 18.6 (14.9–23.0)
Pneumococci
Women 999     65–79
Low 220 n.r. n.r. n.r. 29.1 (22.3–37.1) 29.1 (22.3–37.1)
Middle 635 n.r. n.r. n.r. 36.3 (31.1–41.7) 36.3 (31.1–41.7)
High 144 n.r. n.r. n.r. 27.5 (19.7–37.0) 27.5 (19.7–37.0)
Men 939      
Low 150 n.r. n.r. n.r. 27.8 (20.2–36.9) 27.8 (20.2–36.9)
Middle 536 n.r. n.r. n.r. 29.7 (24.8–35.0) 29.7 (24.8–35.0)
High 253 n.r. n.r. n.r. 30.6 (24.0–38.0) 30.6 (24.0–38.0)
n.r. not rectorded.
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Tab. 5 Vaccination coverage of at least one vaccination dose by sex, age group and residence in eastern or western Germany (including Berlin) 




18–29 30–44 45–64 65–79 Total
Tetanus in the last 10 years
Women 4032  
East 1125 81.5 (74.2–87.1) 81.1 (74.1–86.6) 73.7 (68.5–78.3) 87.2 (81.5–91.3) 79.8 (76.6–82.8)
West 2907 72.3 (66.8–77.2) 67.8 (63.4–72.0) 67.3 (63.6–70.8) 69.7 (65.4–73.7) 68.8 (66.7–70.9)
Men 3649  
East 1031 77.0 (68.1–84.0) 71.9 (62.6–79.7) 77.6 (72.2–82.1) 79.4 (72.8–84.8) 76.5 (73.2–79.5)
West 2618 77.4 (71.5–82.4) 70.2 (65.8–74.3) 71.1 (67.8–74.1) 65.8 (60.8–70.5) 71.1 (68.7–73.3)
Diphtheria in the last 10 years
Women 3792  
East 1068 69.4 (58.4–78.6) 74.2 (65.9–81.1) 64.4 (58.5–69.8) 76.2 (68.3–82.7) 70.2 (66.2–73.9)
West 2724 67.3 (61.7–72.5) 56.1 (51.4–60.7) 55.5 (51.4–59.5) 53.9 (49.2–58.6) 57.4 (54.8–60.0)
Men 3308  
East 977 73.2 (62.6–81.6) 60.1 (51.5–68.0) 57.0 (52.3–61.7) 68.3 (61.5–74.4) 62.9 (59.2–66.5)
West 2331 68.9 (62.3–74.8) 52.2 (47.3–57.0) 47.9 (44.0–51.8) 46.6 (42.0–51.3) 52.6 (49.9–55.3)
Pertussis in the last 10 years
Women 3766  
East 1054 48.6 (37.9–59.5) 25.3 (18.7–33.2) 17.8 (12.7–24.4) 11.2 (6.3–19.2) 22.9 (18.4–28.0)
West 2712 27.2 (22.4–32.7) 9.9 (7.6–12.7) 8.8 (6.8–11.3) 5.8 (3.8–8.5) 11.8 (10.3–13.4)
Men 3317  
East 964 40.7 (29.1–53.5) 19.5 (13.0–28.2) 11.9 (8.7–16.1) 18.9 (12.6–27.3) 20.3 (16.5–24.7)
West 2353 23.0 (18.2–28.6) 7.7 (5.6–10.7) 5.9 (4.4–8.0) 5.8 (3.8–8.8) 9.4 (8.0–11.1)
Poliomyelitis
Women 4021  
East 1103 93.1 (83.7–97.3) 90.5 (83.5–94.7) 83.4 (77.8–87.8) 66.9 (54.9–77.0) 82.5 (77.7–86.4)
West 2918 94.5 (90.5–96.9) 89.1 (84.7–92.3) 90.9 (88.2–93.0) 75.7 (71.3–79.6) 88.0 (86.1–89.7)
Men 3594  
East 1017 96.6 (89.8–98.9) 91.0 (84.2–95.0) 83.2 (76.8–88.2) 57.8 (48.7–66.4) 82.4 (77.9–86.0)
West 2577 89.8 (84.9–93.3) 88.7 (84.4–91.9) 86.5 (83.5–89.1) 69.3 (64.3–73.9) 84.6 (82.3–86.6)
Influenza
Women 4124  
East 1138 55.7 (45.7–65.2) 51.3 (41.6–60.8) 70.5 (64.3–76.1) 82.2 (76.7–86.7) 67.0 (62.7–71.0)
West 2986 22.0 (18.1–26.6) 27.4 (23.3–32.1) 40.0 (36.3–43.9) 65.3 (60.9–69.5) 38.7 (36.5–40.9)
Men 3697  
East 1041 46.9 (36.7–57.4) 45.3 (36.4–54.5) 66.8 (61.5–71.8) 82.0 (76.5–86.4) 61.2 (57.1–65.1)
West 2656 32.0 (26.2–38.4) 33.6 (28.7–38.9) 44.3 (40.0–48.7) 64.5 (59.1–69.5) 42.9 (40.3–45.6)
Hepatitis A
Women 3909  
East 1090 38.9 (28.6–50.2) 35.4 (28.3–43.2) 20.9 (16.9–25.5) 10.6 (7.2–15.4) 24.3 (20.4–28.7)
West 2819 40.2 (35.4–45.2) 34.1 (29.9–38.6) 25.2 (21.9–28.7) 15.5 (12.4–19.2) 28.0 (25.8–30.4)
Men 3480  
East 992 44.7 (34.6–55.3) 35.1 (27.1–43.9) 18.1 (12.7–25.3) 10.0 (6.5–15.2) 25.0 (20.1–30.8)
West 2488 40.6 (34.9–46.6) 34.1 (29.2–39.3) 23.6 (20.6–26.9) 15.3 (12.3–18.9) 27.8 (25.5–30.2)
Hepatitis B
Women 3912  
East 1088 83.6 (74.0–90.1) 32.4 (25.0–40.8) 21.7 (18.1–25.8) 8.8 (5.9–13.1) 30.5 (27.3–34.0)
West 2824 75.0 (69.9–79.5) 36.8 (32.3–41.6) 27.7 (24.3–31.4) 11.7 (9.2–14.9) 35.2 (32.8–37.6)
Men 3464  
East 985 80.2 (70.5–87.2) 31.0 (22.7–40.6) 16.1 (11.4–22.3) 6.7 (4.0–11.0) 29.1 (24.8–33.8)




Vaccination coverage in 
Germany over time
Vaccination coverage recorded in DEGS1 
regarding at least (any) one vaccination 
within the last 10 years increases from 
70.1% (68.3–71.9) to 83.6% (82.3–84.8) 
compared to the values determined 
in GNHIES98 (. Tab. 6). The signifi-
cant increase in the proportion of adults 
who were vaccinated in the decade pri-
or to each survey is due to significant-
ly increased vaccination coverage in 40–
79 year olds. In all age groups, the per-
centage of adults who have received a tet-
anus vaccination within the last 10 years 
improved; the biggest increase can be 
seen in over 69 year olds. 
The clear increase in vaccination cov-
erage against tetanus in 50- to 79-year-
old women offsets the gender difference 
observed 10 years ago. Vaccination cov-
erage for diphtheria has also increased 
significantly; here the greatest increase 
can be observed in the youngest age 
group. Ten years ago, vaccination cov-
erage tended to be higher in men than 
in women, but this trend has now been 
reversed: today, women are significantly 
more likely to be vaccinated against diph-
theria than men. The reversal of this rela-
tionship is due to a 67% increase among 




Tetanus (lockjaw) is a potentially fatal dis-
ease caused by a bacterium found mainly 
in soil that can lead to infection following 
minor injuries to the skin [17]. The vacci-
nation recommendations for tetanus have 
remained unchanged for many years and 
primary immunisation is recommended 
during infancy. In childhood and adoles-
cence, two booster vaccinations are rec-
ommended and, in adulthood, a boost-
er shot should be administered every 
10 years [18].
Lifetime prevalence for tetanus vac-
cinations in DEGS1 is over 95%, yet on-
ly 71.4% of 18–79 year olds have current-
ly adequate immunisation against tetanus. 
Across all age groups there is an associ-
ation between lower vaccination cover-
age and lower SES. As was the case more 
than a decade ago, vaccination coverage 
is better among younger adults than in 
the higher age groups. Vaccination cov-
erage in eastern Germany 20 years after 
reunification is also considerably higher 
than in western Germany. However, the 
general development of tetanus vaccina-
tion coverage is favourable. The propor-
tion of adults currently adequately vacci-
nated against tetanus today is 10 percent-
age points higher than in the years 1997–
1999 in GNHIES98 [19]. Older adults in 
particular are better protected against tet-
anus today than 10 years ago. More adults 
in Germany are vaccinated against tetanus 
than in other European countries (for ex-
ample France 62.3% [20], Spain 60–80% 
[21] and the USA 61.6%). Like in Germa-
ny, the American data also show that vac-
cination gaps increase with age: 64.0% of 
19–49 year olds received a tetanus vacci-
nation within the past 10 years, but the 
figure for over 64 year olds is only 53.4% 
[22].
Pertussis
Pertussis is a highly contagious bacterial 
disease caused by a toxin-producing bac-
terium that presents a particularly serious 
threat to the health of infants and young 
children [23]. Young infants cannot be 
sufficiently protected by vaccinations due 
to their age but at the same time they are 
particularly endangered by whooping 
cough. Preventive vaccination is not only 
of crucial importance for infants, but also 
for older children and adults [24]. Gener-
al pertussis vaccination of all infants and 
small children has been recommended by 
STIKO since 1991. In the German Dem-
ocratic Republic (GDR), the whooping 
cough vaccination was compulsory from 
1964, whereas in the Federal Republic of 
Germany (FRG) this vaccination was only 
Tab. 5 Vaccination coverage of at least one vaccination dose by sex, age group and residence in eastern or western Germany (including Berlin) 




18–29 30–44 45–64 65–79 Total
Measles
Women 2791  
East 774 90.4 (80.0–95.7) 73.9 (66.8–80.0) 25.2 (20.7–30.3) n.r. 53.4 (48.2–58.5)
West 2017 80.7 (75.7–84.9) 36.5 (31.6–41.7) 13.5 (11.0–16.4) n.r. 36.7 (34.0–39.5)
Men 2322  
East 656 92.1 (86.1–95.7) 67.8 (59.2–75.4) 28.6 (23.2–34.7) n.r. 54.3 (50.1–58.5)
West 1666 74.0 (67.6–79.6) 31.4 (26.7–36.6) 12.6 (9.9–15.9) n.r. 33.0 (30.1–36.0)
Pneumococci
Women 1015  
East 301 n.r. n.r. n.r. 57.9 (50.5–64.9) 57.9 (50.5–64.9)
West 714 n.r. n.r. n.r. 27.2 (22.9–32.0) 27.2 (22.9–32.0)
Men 965  
East 292 n.r. n.r. n.r. 49.7 (41.7–57.7) 49.7 (41.7–57.7)
West 673 n.r. n.r. n.r. 24.6 (20.4–29.2) 24.6 (20.4–29.2)
n.r. not recorded.
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recommended from 1969–1974. After this, 
the vaccination was only recommended 
for particular risk groups among children 
under 2 years of age. After increasing in-
cidence of pertussis was observed, above 
all among adolescents and young adults, 
STIKO recommended a pertussis booster 
vaccination in 2000 for children and ado-
lescents aged 9–17 years. Due to the limit-
ed duration of immunity achieved by the 
vaccination of around 4–12 years [25], an 
additional booster vaccination was rec-
ommended in 2006 for children aged 
5–6 years old. The STIKO had decided in 
2004 to expand the indication for a pre-
ventative pertussis vaccination, according 
to which persons with close contact to in-
fants were to be vaccinated against pertus-
sis (before birth of the child if possible). In 
2009 an additional pertussis vaccination 
in adulthood with a combination vaccine 
including tetanus and diphtheria was rec-
ommended at the next due tetanus–diph-
theria vaccination [26].
The estimated vaccination coverage in 
adults (34%) shows that pertussis vaccina-
tion protection is still insufficient in Ger-
many. In light of the limited duration of 
immunity against pertussis both after vac-
cination as well as after having had per-
tussis, the low 10-year prevalences (wom-
en 13.7%, men 11.4%) in particular under-
line the unsatisfactory situation in Ger-
many; this shortcoming is significant-
ly more pronounced in western Germa-
ny than in eastern Germany. When in-
terpreting the results, however, it must be 
considered that the additional recommen-
dation of a vaccination for all adults was 
only made in 2009 and that implementa-
tion is scheduled gradually in the context 
of due booster vaccinations against teta-
nus and diphtheria.
A pertussis vaccination for adults is 
currently only recommended in a few 
countries (Australia, Canada, USA, France 
and Germany) [24]. Data regarding vacci-
nation coverage achieved in adults to date 
are available only on a very limited scale. 
Two years after the Advisory Committee 
on Immunization Practices (ACIP) in the 
USA issued the recommendation that all 
adults should receive a pertussis vaccine 
with their next tetanus vaccination, the re-
sults of the National Immunization Sur-
vey in 2007 showed that the proportion 
of pertussis vaccines combined with tet-
anus vaccines was only 20.7% [27]. How-
ever, the proportion of pertussis vaccines 
combined with tetanus vaccines increased 
significantly in the following years and av-
eraged 52.1% in surveys conducted from 
2005–2008 [28].
Influenza
Seasonal influenza (flu) is an acute viral 
infection that appears among the pop-
ulation of the northern hemisphere al-
most every winter in clusters lasting sev-
eral weeks, known as the influenza wave. 
Because influenza viruses are highly vari-
Tab. 6 Comparison of vaccination coverage of at least one vaccination dose from DEGS1 and GNHIES98 by sex and age in percent with 95% 




18–29 30–39 40–49 50–59 60–69 70–79 Total
DEGS vaccinated in the last 10 years (any vaccination)
Women 4043 89.1 (85.4–91.9) 76.7 (71.2–81.4) 82.6 (79.2–85.6) 79.6 (75.9–82.9) 84.5 (80.8–87.6) 85.1 (80.9–88.4) 83.0 (81.2–84.6)
Men 3637 89.6 (85.4–92.7) 82.3 (77.2–86.4) 80.7 (76.7–84.1) 84.3 (81.0–87.2) 84.8 (81.5–87.7) 82.9 (78.1–86.7) 84.2 (82.3–85.8)
Total 7680 89.3 (86.8–91.4) 79.5 (75.8–82.7) 81.7 (79.2–83.9) 82.0 (79.5–84.2) 84.6 (82.2–86.8) 84.1 (81.0–86.7) 83.6 (82.3–84.8)
DEGS tetanus in the last 10 years
Women 4032 73.7 (68.8–78.0) 66.6 (61.1–71.6) 70.9 (66.7–74.8) 69.4 (65.4–73.1) 71.5 (67.1–75.6) 71.8 (67.1–76.1) 70.7 (68.8–72.6)
Men 3649 77.4 (72.2–81.8) 70.6 (64.8–75.7) 71.2 (66.6–75.4) 71.7 (67.6–75.4) 72.1 (67.7–76.1) 67.4 (61.8–72.5) 72.0 (70.0–74.0)
Total 7681 75.6 (71.8–78.9) 68.6 (64.4–72.4) 71.1 (67.9–74.0) 70.5 (67.6–73.3) 71.8 (68.4–75.0) 69.8 (66.2–73.2) 71.4 (69.8–72.9)
DEGS diphtheria in the last 10 years
Women 3792 67.6 (62.6–72.3) 55.4 (49.9–60.8) 61.0 (56.0–65.8) 57.1 (52.7–61.4) 59.1 (54.6–63.5) 55.7 (50.1–61.2) 59.6 (57.3–62.0)
Men 3308 69.6 (63.9–74.8) 54.3 (48.4–60.0) 52.5 (46.9–58.1) 48.4 (44.1–52.7) 50.5 (45.6–55.4) 49.8 (44.4–55.2) 54.5 (52.1–56.8)
Total 7100 68.6 (64.9–72.1) 54.9 (50.9–58.8) 56.8 (52.8–60.7) 52.8 (49.8–55.8) 55.0 (51.5–58.4) 53.0 (49.2–56.9) 57.1 (55.3–58.9)
GNHIES98 vaccinated in the last 10 years (any vaccination)
Women 3612 83.4 (79.6–86.7) 74.5 (71.0–77.7) 65.9 (61.7–69.8) 62.9 (58.2–67.4) 62.0 (56.4–67.2) 59.9 (52.5–66.9) 68.3 (66.0–70.4)
Men 3351 88.9 (85.7–91.5) 78.7 (74.4–82.4) 69.6 (65.2–73.7) 67.2 (62.5–71.6) 64.9 (59.2–70.2) 58.6 (50.7–66.1) 72.1 (69.9–74.1)
Total 6963 86.2 (83.6–88.4) 76.6 (73.8–79.3) 67.8 (64.7–70.8) 65.1 (61.5–68.5) 63.4 (59.0–67.6) 59.3 (53.5–64.8) 70.1 (68.3–71.9)
GNHIES98 tetanus in the last 10 years
Women 3554 75.9 (71.5–79.8) 66.7 (62.7–70.4) 59.5 (55.3–63.6) 54.4 (49.9–58.7) 49.1 (43.5–54.6) 37.6 (30.9–44.7) 57.9 (55.7–60.0)
Men 3295 84.7 (80.9–87.9) 75.2 (70.6–79.3) 63.9 (59.4–68.1) 60.5 (55.4–65.4) 57.5 (51.9–62.9) 46.1 (38.6–53.8) 65.6 (63.3–67.9)
Total 6849 80.2 (77.4–82.8) 71.0 (67.9–74.0) 61.7 (58.6–64.8) 57.4 (53.8–60.9) 53.2 (48.8–57.5) 41.4 (36.2–46.8) 61.7 (59.8–63.6)
GNHIES98 Diphtheria in the last 10 years
Women 3423 25.3 (20.9–30.2) 33.6 (29.3–38.1) 35.2 (31.0–39.8) 37.4 (33.1–41.9) 43.7 (39.0–48.5) 47.5 (41.1–54.1) 36.8 (34.7–38.9)
Men 3047 35.3 (30.4–40.7) 41.7 (37.1–46.5) 40.3 (35.5–45.3) 41.8 (37.7–46.0) 43.2 (37.7–48.9) 46.1 (38.0–54.3) 41.2 (38.7–43.8)




able, one single immunisation is not suf-
ficient. STIKO recommends an annual in-
fluenza vaccination with a vaccine adapt-
ed to the circulating viruses for, amongst 
others, persons over 60, persons with 
chronic diseases and persons at higher 
risk due to occupational exposure [18]. In 
2003, the WHO laid down a target vacci-
nation coverage of 75% for older persons 
and the chronically ill by 2010 [29].
Although the lifetime prevalence for 
flu vaccinations in DEGS1 stratified by age 
shows that vaccination coverage is high-
er in older men as compared to younger 
men, even the lifetime prevalence among 
adults over 60 is far below the annual rate 
of 75% recommended by the WHO. In 
eastern Germany, the proportion (82%) of 
70–79 year olds who have been vaccinated 
against influenza in the past suggests that 
the figure is likely approaching the WHO 
target. Vaccination coverage for influenza 
in all age groups is higher in eastern Ger-
many than in western Germany and this 
indicates significantly greater acceptance 
of vaccinations by the population in those 
regions.
The lifetime prevalence of influenza 
vaccination of 44.7% among 18–79 year 
olds recorded in DEGS1 is considerably 
lower than the result (55.2%) of a tele-
phone survey on vaccination coverage 
among over 13 year olds in Germany 
conducted in 2006/2007 with 2,007 re-
spondents [30]. However, with figures of 
63.3% among 60–69 year olds and 68.3% 
among 70–79 year olds, the proportion 
of over 59 year olds who have received at 
least one influenza vaccination is signif-
icantly higher than found in the survey 
of influenza vaccinations in GEDA (Ger-
man Health Update, annual telephone 
surveys at the Robert Koch Institute) 
based on the previous season (2007/2008: 
56.6%; 2008/2009: 55.2%). Although the 
vaccination coverage recorded in DESG1 
indicates a somewhat higher general ac-
ceptance of the flu vaccination among 
the elderly in particular, the differenti-
ated evaluations from GEDA studies re-
garding vaccinations in the previous flu 
season show that the recommendation 
to repeat flu vaccinations annually is not 
being implemented satisfactorily [31]. In 
a comparison with France, Italy, Spain 
and Great Britain, the recommendation 
that older men and women in particular 
should be vaccinated against influenza 
seems to be implemented worst of all in 
Germany [30]. The discrepancy between 
the rate of influenza vaccinations planned 
by respondents for the next season and 
the vaccination rates subsequently re-
corded is particularly high in Germany 
[32]. In Germany, like in other countries, 
medical consultation is of great impor-
tance for positive vaccination decisions 
[31, 33, 34]. However, a survey of doctors’ 
practices carried out in 2009 shows that 
only two thirds of them motivate high-
risk patient groups to receive the influen-
za vaccination [35]. A similar survey of 
American physicians in 2001 showed that 
more than three in four doctors recom-
mend an influenza vaccination [36].
Methodology
The vaccination rates reported here are 
based on vaccinations documented in 
the vaccination card as well as self-re-
ported vaccinations; the information is 
therefore based on multiple sources. The 
reason for this approach was that self-re-
ported vaccination data are subject to re-
call bias, which can lead to both over- and 
underestimation. Strength and direction 
depend on the type of surveyed vaccina-
tion [37, 38, 39]. On the other hand, vac-
cinations of adults in particular are often 
not fully documented in the vaccination 
card (follow-up documents, lost vaccina-
tion cards, vaccinations documented on-
ly on notes or at the doctor’s practice/hos-
pital). Therefore, in a survey based only 
on vaccination cards, underestimation 
would be likely. In DEGS1, incomplete 
vaccination documentation among older 
adults in particular meant that addition-
al, self-reported vaccinations were taken 
into account. This approach led to high-
er vaccination coverage than would have 
been obtained solely through an evalua-
tion of vaccination cards; this was partic-
ularly significant for influenza vaccina-
tion coverage.
The methodological approach to col-
lecting data for vaccination coverage in 
DESG1 was therefore motivated by the 
attempt to guarantee the highest sensitiv-
ity possible (“missing” no vaccinations) 
on the one hand while ensuring the va-
lidity of data on the other. The proportion 
of participants for whom it was possible 
to survey vaccination status based sole-
ly on medically documented vaccinations 
was 40.8%. This figure is lower than in a 
Dutch study where either validation us-
ing vaccination cards or verification via 
regional vaccination centres was possible 
for 68% of participants [40].
The proportion of missing informa-
tion or “Don’t know” answers can al-
so provide valuable information con-
cerning the validity of the recorded data. 
With regard to pertussis vaccination sta-
tus, no data could be obtained in DEGS1 
for 11% of adults; almost all missing in-
formation concerns adults whose vacci-
nation status was requested in CAPI in-
terviews. Similar problems with self-re-
ported pertussis vaccinations were ob-
served in the National Health Interview 
Survey (NHIS) when surveying adults in 
the USA. Of persons who declared that 
they had received a tetanus vaccination 
in the years 2005–2008, 69.8% could not 
specify whether this vaccine contained a 
pertussis component [28].
On the other hand, differences in vac-
cination coverage between participants 
who submitted a vaccination card and 
those whose vaccination status is based 
on self-reported data can be due to real 
differences between the groups: seroep-
idemiological studies on the prevalence 
of IgG antibodies against measles in chil-
dren with and without vaccination cards 
showed lower vaccination coverage in 
children for whom no vaccination card 
was brought to the examination [41].
The comparison with data from tele-
phone studies in GEDA 2009 gives no in-
dication of differences in vaccination cov-
erage rates due to methodology. The da-
ta for lifetime prevalence of tetanus vac-
cination obtained in DEGS1 via the multi-
mode process (96.0%) show comparative-
ly high coverage, as was the case in GEDA 
2009 (95.4%) [31]; the 10-year prevalence 
in DEGS1 (71.4%) is only slightly lower 
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